$FATE
Fate Therapeutics Inc

2022 Q4 Form 10-Q Financial Statement

#000095017022021840 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $44.36M $14.98M $14.23M
YoY Change 159.86% 5.31% 88.21%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $21.58M $21.56M $15.72M
YoY Change 27.44% 37.14% 88.24%
% of Gross Profit
Research & Development $87.19M $79.82M $53.13M
YoY Change 25.43% 50.23% 73.1%
% of Gross Profit
Depreciation & Amortization $4.842M $3.193M $1.519M
YoY Change 119.49% 110.2% 94.74%
% of Gross Profit
Operating Expenses $108.8M $101.4M $68.85M
YoY Change 25.82% 47.24% 76.33%
Operating Profit -$86.39M -$54.62M
YoY Change 58.16% 73.48%
Interest Expense $8.056M $2.678M $11.32M
YoY Change 958.61% -76.33% -141.6%
% of Operating Profit
Other Income/Expense, Net $0.00 $2.828M $11.32M
YoY Change -75.01% -141.6%
Pretax Income -$56.36M -$83.56M -$43.31M
YoY Change -17.86% 92.95% -26.2%
Income Tax
% Of Pretax Income
Net Earnings -$56.36M -$83.56M -$43.31M
YoY Change -17.86% 92.95% -26.2%
Net Earnings / Revenue -127.07% -557.79% -304.45%
Basic Earnings Per Share -$0.86 -$0.45
Diluted Earnings Per Share -$0.58 -$0.86 -$453.9K
COMMON SHARES
Basic Shares Outstanding 97.17M 97.00M 95.41M
Diluted Shares Outstanding 97.02M 95.41M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $436.2M $505.1M $678.7M
YoY Change -29.17% -25.57% 38.85%
Cash & Equivalents $61.33M $82.09M $129.2M
Short-Term Investments $374.9M $423.0M $549.5M
Other Short-Term Assets $27.37M $19.97M $7.701M
YoY Change 210.07% 159.32% 63.85%
Inventory
Prepaid Expenses
Receivables $38.48M $10.22M $7.311M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $502.1M $535.3M $693.7M
YoY Change -20.74% -22.83% 39.64%
LONG-TERM ASSETS
Property, Plant & Equipment $110.0M $109.1M $74.62M
YoY Change 20.2% 46.24% -15.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $4.942M $13.94M $124.9M
YoY Change -95.09% -88.84% 846.04%
Other Assets $33.00K $33.00K $9.000K
YoY Change 0.0% 266.67% -99.94%
Total Long-Term Assets $203.5M $214.0M $290.9M
YoY Change -29.36% -26.42% 124.43%
TOTAL ASSETS
Total Short-Term Assets $502.1M $535.3M $693.7M
Total Long-Term Assets $203.5M $214.0M $290.9M
Total Assets $705.6M $749.3M $984.6M
YoY Change -23.43% -23.89% 57.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.265M $9.593M $6.439M
YoY Change -4.03% 48.98% 74.03%
Accrued Expenses $53.93M $50.15M $54.00M
YoY Change 27.16% -7.14% 265.33%
Deferred Revenue $42.23M $35.24M $23.55M
YoY Change 96.56% 49.68%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $114.1M $103.9M $91.88M
YoY Change 40.31% 13.12% 69.54%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $107.6M $127.4M $162.4M
YoY Change -33.32% -21.53% 9.77%
Total Long-Term Liabilities $107.6M $127.4M $162.4M
YoY Change -33.32% -21.53% 9.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $114.1M $103.9M $91.88M
Total Long-Term Liabilities $107.6M $127.4M $162.4M
Total Liabilities $221.6M $231.3M $254.2M
YoY Change -8.65% -9.0% 25.8%
SHAREHOLDERS EQUITY
Retained Earnings -$1.051B -$994.4M -$700.5M
YoY Change 36.63% 41.97% 39.03%
Common Stock $97.00K $97.00K $95.00K
YoY Change 1.04% 2.11% 9.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $483.9M $518.0M $730.3M
YoY Change
Total Liabilities & Shareholders Equity $705.6M $749.3M $984.6M
YoY Change -23.43% -23.89% 57.17%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$56.36M -$83.56M -$43.31M
YoY Change -17.86% 92.95% -26.2%
Depreciation, Depletion And Amortization $4.842M $3.193M $1.519M
YoY Change 119.49% 110.2% 94.74%
Cash From Operating Activities -$75.39M -$55.05M -$33.38M
YoY Change 7.25% 64.93% 8.57%
INVESTING ACTIVITIES
Capital Expenditures $6.677M -$8.676M -$14.74M
YoY Change -136.35% -41.12% 1451.05%
Acquisitions
YoY Change
Other Investing Activities $59.79M $89.05M $92.69M
YoY Change -33.31% -3.93% -274.27%
Cash From Investing Activities $53.11M $80.38M $77.96M
YoY Change -25.49% 3.1% -244.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.517M 1.487M 7.942M
YoY Change -55.62% -81.28% 753.98%
NET CHANGE
Cash From Operating Activities -75.39M -55.05M -33.38M
Cash From Investing Activities 53.11M 80.38M 77.96M
Cash From Financing Activities 1.517M 1.487M 7.942M
Net Change In Cash -20.76M 26.82M 52.53M
YoY Change -571.5% -48.94% -162.57%
FREE CASH FLOW
Cash From Operating Activities -$75.39M -$55.05M -$33.38M
Capital Expenditures $6.677M -$8.676M -$14.74M
Free Cash Flow -$82.07M -$46.37M -$18.64M
YoY Change 58.05% 148.77% -37.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7690000
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseMember
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36076
dei Entity Registrant Name
EntityRegistrantName
FATE THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-1311552
dei Entity Address Address Line1
EntityAddressAddressLine1
12278 Scripps Summit Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92131
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
875-1800
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
FATE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseMember
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseMember
CY2021Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseMember
dei Entity Central Index Key
EntityCentralIndexKey
0001434316
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
97170443
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82093000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
133583000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10223000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8676000
CY2022Q3 fate Short Term Investments And Related Maturity Receivables
ShortTermInvestmentsAndRelatedMaturityReceivables
423043000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5577000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
103938000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
81284000
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12407000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
27124000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
233263000
CY2022Q3 fate Cirm Award Liability Noncurrent
CIRMAwardLiabilityNoncurrent
800000
CY2021Q4 fate Cirm Award Liability Noncurrent
CIRMAwardLiabilityNoncurrent
800000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
105164000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
109241000
CY2022Q3 fate Stock Price Appreciation Milestones Liabilities Non Current
StockPriceAppreciationMilestonesLiabilitiesNonCurrent
9037000
CY2021Q4 fate Stock Price Appreciation Milestones Liabilities Non Current
StockPriceAppreciationMilestonesLiabilitiesNonCurrent
24168000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
146004000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21555000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15718000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
62648000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40385000
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
101372000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
68848000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
us-gaap Operating Expenses
OperatingExpenses
295911000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
us-gaap Operating Expenses
OperatingExpenses
186389000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97112209
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-86391000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97112209
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-54623000
us-gaap Operating Income Loss
OperatingIncomeLoss
-243967000
us-gaap Operating Income Loss
OperatingIncomeLoss
-147612000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95726962
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95726962
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
97000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1787000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
289000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2962000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
96000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1515597000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1012000
CY2022Q3 fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-891000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1448584000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
921455000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3253000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-762000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-994441000
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
2708000
CY2021Q4 fate Short Term Investments And Related Maturity Receivables
ShortTermInvestmentsAndRelatedMaturityReceivables
482327000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19970000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8826000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14981000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14225000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
535329000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
633412000
CY2022Q3 us-gaap Long Term Investments
LongTermInvestments
13939000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
100664000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
109118000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
91529000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
67378000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51944000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38777000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
70720000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
15227000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
15227000
CY2022Q3 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
8325000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
79817000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53130000
CY2021Q4 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
9870000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2022Q3 us-gaap Assets
Assets
749349000
CY2021Q4 us-gaap Assets
Assets
921455000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9593000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8612000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
50149000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42412000
CY2022Q3 fate Cirm Award Liability Current
CIRMAwardLiabilityCurrent
3200000
CY2021Q4 fate Cirm Award Liability Current
CIRMAwardLiabilityCurrent
3200000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
35241000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
21483000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5755000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-769083000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
518003000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
678838000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
749349000
CY2021Q3 fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-11026000
fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-15131000
fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-3070000
CY2022Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
150000
CY2021Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
516000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2828000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11315000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
18609000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4082000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-83563000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-43308000
us-gaap Net Income Loss
NetIncomeLoss
-225358000
us-gaap Net Income Loss
NetIncomeLoss
-143530000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
128000
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
13000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2491000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-959000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-143000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-83435000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
440222000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
431746000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-43295000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-227849000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-143673000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.86
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.86
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.52
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97023506
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97023506
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95409201
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95409201
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96692974
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96692974
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94396485
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94396485
us-gaap Profit Loss
ProfitLoss
-225358000
us-gaap Profit Loss
ProfitLoss
-143530000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8916000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3644000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
59341000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39770000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-989000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3995000
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
1546000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-11057000
fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-15131000
fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
-3070000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1547000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1795000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10924000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1921000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
10865000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
16287000
fate Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
-557000
fate Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
2392000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-172819000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-92577000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28889000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
32335000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
297694000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
794712000
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
329757000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
113639000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-395301000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17265000
fate Proceeds From Public Offering Of Common Stock And Issuance Of Pre Funded Warrants
ProceedsFromPublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants
411766000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
20680000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7690000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
449711000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-51490000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38167000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
148810000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
182574000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
97320000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
144407000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1988000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3622000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
682000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1546000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s unaudited condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The preparation of the Company’s unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited condensed consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s unaudited condensed consolidated financial statements relate to its stock price appreciation milestone obligations, contracts containing leases, accrued expenses, stock-based compensation, and the estimated total costs expected to be incurred under the Company’s collaboration agreements. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></p>
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19331000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2088000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-65690000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
633393000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82093000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
129180000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
15227000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
15227000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
97320000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
144407000
CY2022Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
15200000
CY2021Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
15200000
CY2020 fate Period To Treat Award As Grant If Award Not Treated As Loan
PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan
P10Y
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3184000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-83600000
us-gaap Net Income Loss
NetIncomeLoss
-225400000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27300000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-43300000
us-gaap Net Income Loss
NetIncomeLoss
-143500000
CY2021 fate Investment Maturity Date Range
InvestmentMaturityDateRange
1 or les
fate Expected Ressarch Services Period
ExpectedRessarchServicesPeriod
P4Y
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20542000
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
3254000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
414126000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
763000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022Q3 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2021Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022Q3 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2021Q3 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2022Q3 us-gaap Share Price
SharePrice
22.41
CY2022Q3 us-gaap Share Price
SharePrice
22.41
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-531000
CY2022Q3 fate Transfer Of Assets From Level1 To Level2
TransferOfAssetsFromLevel1ToLevel2
0
CY2022Q3 fate Transfer Of Assets From Level2 To Level1
TransferOfAssetsFromLevel2ToLevel1
0
fate Fair Value Liabilities Level1 To Level3 Transfers Amount
FairValueLiabilitiesLevel1ToLevel3TransfersAmount
0
fate Fair Value Liabilities Level2 To Level3 Transfers Amount
FairValueLiabilitiesLevel2ToLevel3TransfersAmount
0
fate Fair Value Liabilities Level3 To Level2 Transfers Amount
FairValueLiabilitiesLevel3ToLevel2TransfersAmount
0
fate Fair Value Liabilities Level3 To Level1 Transfers Amount
FairValueLiabilitiesLevel3ToLevel1TransfersAmount
0
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
730332000
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
17403000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
18358000
CY2022Q3 fate Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
13845000
CY2021Q4 fate Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
12344000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
18901000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11710000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
50149000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42412000
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
These leases have terms varying from one to approximately sixteen years, with renewal options of up to ten years
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y8M12D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0828
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
678838000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3001000
CY2022Q3 fate Straight Line Lease Expense
StraightLineLeaseExpense
3620000
CY2021Q3 fate Straight Line Lease Expense
StraightLineLeaseExpense
3538000
fate Straight Line Lease Expense
StraightLineLeaseExpense
10754000
fate Straight Line Lease Expense
StraightLineLeaseExpense
10617000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
615000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
529000
us-gaap Variable Lease Cost
VariableLeaseCost
1910000
us-gaap Variable Lease Cost
VariableLeaseCost
1120000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
4235000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
4067000
us-gaap Operating Lease Cost
OperatingLeaseCost
12664000
us-gaap Operating Lease Cost
OperatingLeaseCost
11737000
CY2021Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3892000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
14597000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
14836000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
15087000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
15540000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
16006000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
101636000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
181594000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
70675000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
110919000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19468000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13540000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
59341000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39770000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
13000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-43308000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-76105000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
580483000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1487000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19468000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
128000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-83563000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
518003000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
384445000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5648000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12976000
CY2021Q1 fate Public Offering Of Common Stock And Issuance Of Pre Funded Warrants
PublicOfferingOfCommonStockAndIssuanceOfPreFundedWarrants
432445000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-330000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-45089000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
790095000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3681000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13254000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
174000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-55133000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
752071000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8016000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13540000

Files In Submission

Name View Source Status
fate-20220930_lab.xml Edgar Link unprocessable
0000950170-22-021840-index-headers.html Edgar Link pending
0000950170-22-021840-index.html Edgar Link pending
0000950170-22-021840.txt Edgar Link pending
0000950170-22-021840-xbrl.zip Edgar Link pending
fate-20220930.htm Edgar Link pending
fate-20220930.xsd Edgar Link pending
fate-20220930_cal.xml Edgar Link unprocessable
fate-20220930_def.xml Edgar Link unprocessable
fate-ex31_1.htm Edgar Link pending
fate-ex31_2.htm Edgar Link pending
fate-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
fate-20220930_pre.xml Edgar Link unprocessable
fate-20220930_htm.xml Edgar Link completed
report.css Edgar Link pending
Show.js Edgar Link pending